Sumitomo Pharma Co., Ltd. (TYO:4506)
Japan · Delayed Price · Currency is JPY 1,565.50
-54.50 (-3.36%)
May 19, 2026, 1:55 PM JST
Sumitomo Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 453,294 | 398,832 | 314,558 | 555,544 | 560,035 | |
Revenue Growth (YoY) | 13.66% | 26.79% | -43.38% | -0.80% | 8.54% |
Cost of Revenue | 196,401 | 153,437 | 126,577 | 178,919 | 157,127 |
Gross Profit | 256,893 | 245,395 | 187,981 | 376,625 | 402,908 |
Selling, General & Admin | 162,557 | 160,386 | 397,705 | 339,212 | 217,339 |
Research & Development | 43,996 | 49,865 | 112,637 | 131,858 | 94,903 |
Other Operating Expenses | -2,552 | 1,902 | 942 | -2,200 | -1,043 |
Operating Expenses | 204,001 | 232,372 | 543,117 | 502,974 | 342,941 |
Operating Income | 52,892 | 13,023 | -355,136 | -126,349 | 59,967 |
Interest Expense | -10,192 | -6,221 | -3,893 | -2,640 | -2,970 |
Interest & Investment Income | 3,198 | 1,421 | 2,839 | 5,486 | 1,175 |
Earnings From Equity Investments | 2,285 | -905 | - | - | - |
Currency Exchange Gain (Loss) | - | -4,942 | 32,829 | 26,308 | 24,530 |
Other Non Operating Income (Expenses) | - | -1,451 | -30 | -95 | -8 |
EBT Excluding Unusual Items | 48,183 | 925 | -323,391 | -97,290 | 82,694 |
Gain (Loss) on Sale of Investments | - | 13,537 | -224 | 24,735 | - |
Gain (Loss) on Sale of Assets | 49,043 | 3,149 | 501 | 24,635 | 267 |
Other Unusual Items | 3,118 | - | - | - | - |
Pretax Income | 100,344 | 17,611 | -323,114 | -47,920 | 82,961 |
Income Tax Expense | -6,521 | -6,024 | -8,185 | 48,794 | 42,361 |
Earnings From Continuing Operations | 106,865 | 23,635 | -314,929 | -96,714 | 40,600 |
Minority Interest in Earnings | - | -1 | -40 | 22,202 | 15,813 |
Net Income | 106,865 | 23,634 | -314,969 | -74,512 | 56,413 |
Net Income to Common | 106,865 | 23,634 | -314,969 | -74,512 | 56,413 |
Net Income Growth | 352.17% | - | - | - | 0.34% |
Shares Outstanding (Basic) | 397 | 397 | 397 | 397 | 397 |
Shares Outstanding (Diluted) | 397 | 397 | 397 | 397 | 397 |
EPS (Basic) | 268.99 | 59.49 | -792.79 | -187.55 | 141.99 |
EPS (Diluted) | 268.99 | 59.49 | -792.79 | -187.55 | 141.99 |
EPS Growth | 352.17% | - | - | - | 0.34% |
Free Cash Flow | 67,106 | 8,002 | -252,664 | 3,470 | 23,892 |
Free Cash Flow Per Share | 168.91 | 20.14 | -635.97 | 8.73 | 60.14 |
Dividend Per Share | - | - | - | 21.000 | 28.000 |
Dividend Growth | - | - | - | -25.00% | - |
Gross Margin | 56.67% | 61.53% | 59.76% | 67.79% | 71.94% |
Operating Margin | 11.67% | 3.26% | -112.90% | -22.74% | 10.71% |
Profit Margin | 23.57% | 5.93% | -100.13% | -13.41% | 10.07% |
Free Cash Flow Margin | 14.80% | 2.01% | -80.32% | 0.63% | 4.27% |
EBITDA | 73,678 | 38,585 | -317,371 | -85,086 | 98,315 |
EBITDA Margin | 16.25% | 9.67% | -100.89% | -15.32% | 17.55% |
D&A For EBITDA | 20,786 | 25,562 | 37,765 | 41,263 | 38,348 |
EBIT | 52,892 | 13,023 | -355,136 | -126,349 | 59,967 |
EBIT Margin | 11.67% | 3.26% | -112.90% | -22.74% | 10.71% |
Effective Tax Rate | - | - | - | - | 51.06% |
Advertising Expenses | - | 25,000 | 42,372 | 59,857 | 37,780 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.